Cargando…

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis

Detalles Bibliográficos
Autor principal:	Kim, Won Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Pediatric Society 2013
Materias:	Retraction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693047/ https://www.ncbi.nlm.nih.gov/pubmed/23807895 http://dx.doi.org/10.3345/kjp.2013.56.6.269

Ejemplares similares

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis
por: YANG, GUANG, et al.
Publicado: (2015)

Radiological Characteristics of Renal Lesions During Tuberous Sclerosis Complex: Impact of Mechanistic Target of Rapamycin Inhibitor Treatment
por: Pfirmann, Pierre, et al.
Publicado: (2022)

Retraction: Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts
por: Zou, Junjie, et al.
Publicado: (2012)

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Retracted: Inhibition of Nasopharyngeal Carcinoma by Beta-Lapachone Occurs by Targeting the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Pathway, Reactive Oxygen Species (ROS) Production, and Autophagy Induction
por: Han, Yongqing, et al.
Publicado: (2021)

Retraction: Rapamycin Inhibits Proliferation of Hemangioma Endothelial Cells by Reducing HIF-1-Dependent Expression of VEGF
Publicado: (2020)

New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma
por: Agulnik, Mark
Publicado: (2012)

Retracted: Antioxidant Activity and Characterization of One New Polysaccharide Obtained from Perigord Truffle (Tuber huidongense)
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2018)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
por: Zhang, Fengli, et al.
Publicado: (2021)

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin
por: Khadir, Fatemeh, et al.
Publicado: (2018)

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
por: Govindarajan, Baskaran, et al.
Publicado: (2012)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
por: Lu, Yiyang, et al.
Publicado: (2020)

Retraction: Optimization of diosgenin extraction from Dioscorea deltoidea tubers using response surface methodology and artificial neural network modelling
Publicado: (2023)

Retracted: Girinimbine Inhibits the Proliferation of Human Ovarian Cancer Cells In Vitro via the Phosphatidylinositol-3-Kinase (PI3K)/Akt and the Mammalian Target of Rapamycin (mTOR) and Wnt/β-Catenin Signaling Pathways
por: Xin, Qiu, et al.
Publicado: (2021)

Biologic targeting in the treatment of inflammatory bowel diseases [Retraction]
Publicado: (2014)

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
por: Sato, Atsushi, et al.
Publicado: (2012)

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
por: Cabrera-López, Cristina, et al.
Publicado: (2012)

Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
por: Sadowski, Krzysztof, et al.
Publicado: (2022)

The Efficacy and Safety of Rapamycin in Children with Tuberous Sclerosis: A Cross-sectional Study
por: TEHRANI, Fateme, et al.
Publicado: (2023)

Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
por: Leal, Rita, et al.
Publicado: (2017)

Retracted: Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells In Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway
por: Li, Chao, et al.
Publicado: (2021)

Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy?
por: Chan, Jung-Yi Lisa, et al.
Publicado: (2014)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

Monoamine Depletion by Reuptake Inhibitors [Retraction]
Publicado: (2020)

Retracted: Deep Learning Target Detection System for Sewage Treatment
por: Intelligence and Neuroscience, Computational
Publicado: (2023)

Retracted: Eye Sign is an Alternative for Evaluation of the Microcirculation in Patients with Systemic Sclerosis
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Efficient miRNA Inhibitor with GO-PEI Nanosheets for Osteosarcoma Suppression by Targeting PTEN [Retraction]
Publicado: (2023)

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma
por: Jin, Hong-Guang, et al.
Publicado: (2018)

Electroacupuncture induces weight loss by regulating tuberous sclerosis complex 1-mammalian target of rapamycin methylation and hypothalamic autophagy in high-fat diet-induced obese rats
por: Yao, Junpeng, et al.
Publicado: (2022)

Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
por: Messina, Michael P, et al.
Publicado: (2007)

Retraction Note: Distinct Repressive Properties of the Mammalian and Fish Orphan Nuclear Receptors SHP and DAX-1
por: Park, Yun-Yong, et al.
Publicado: (2018)

Tuberous Sclerosis Associated with Polycystic Kidney Disease: Effects of Rapamycin after Renal Transplantation
por: Rosado, C., et al.
Publicado: (2013)

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008)

Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
por: Li, Chenggang, et al.
Publicado: (2014)

Retracted: KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma
por: International, BioMed Research
Publicado: (2023)

Retracted: Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT Signalling Pathway
por: Fang, Kaifeng, et al.
Publicado: (2021)

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
por: Lee, Nancy, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_j62g59l2s708hgo9jhiqfr7t8t